Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Vertex Pharmaceuticals Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net fixed asset turnover
Net fixed asset turnover (including operating lease, right-of-use asset)
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of long-term activity ratios indicates a period of evolving asset efficiency, characterized by an initial improvement in fixed asset utilization followed by a notable decline in efficiency metrics related to right-of-use assets and overall asset turnover.

Net Fixed Asset Turnover
A consistent upward trend was observed from March 2022, where the ratio stood at 7.18, reaching a peak of 9.51 in September 2024. This period suggests an increase in the efficiency of generating revenue from fixed assets. However, a subsequent downward trend emerged from December 2024, with the ratio contracting to 7.60 by March 2026, indicating a reduction in the revenue-generating capacity of fixed assets relative to their net book value.
Net Fixed Asset Turnover Including Operating Lease (Right-of-Use Asset)
This metric followed a growth trajectory from 5.53 in March 2022 to a high of 6.86 in March 2024. Following this peak, a sharp and significant decline occurred, dropping to 4.23 by September 2024 and continuing a downward trajectory to 3.71 by March 2026. The divergence between this ratio and the standard net fixed asset turnover suggests a substantial increase in right-of-use assets, likely due to new long-term lease commitments, which has diluted the turnover efficiency.
Total Asset Turnover
Total asset utilization exhibited a general downward trend over the analyzed period. Starting at 0.56 in March 2022, the ratio declined to a low of 0.43 by March 2024. While a temporary increase to 0.51 was recorded in June 2024, the ratio remained relatively stagnant thereafter, ending at 0.46 in March 2026. This pattern reflects a marginal decrease in the company's ability to generate sales from its total asset base.
Equity Turnover
Equity turnover demonstrated a gradual decline from 0.73 in March 2022 to 0.55 in March 2024. A recovery was noted in June 2024, with the ratio rising to 0.70. For the remainder of the period, the ratio fluctuated within a narrow range, concluding at 0.63 in March 2026. The overall trend suggests that while equity growth initially outpaced revenue growth, the relationship stabilized in the latter half of the period.

Net Fixed Asset Turnover

Vertex Pharmaceuticals Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Property and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Net fixed asset turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Property and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The net fixed asset turnover ratio exhibits a cyclical trajectory over the analyzed period, characterized by an initial phase of efficiency gains, a temporary peak in productivity, and a subsequent decline associated with accelerated capital expenditure.

Revenue and Asset Growth Trends
Revenues demonstrated a consistent upward trend for the majority of the period, rising from 2,097,500 thousand US$ in March 2022 to a peak of 3,190,000 thousand US$ in December 2025. Concurrently, net property and equipment increased from 1,107,400 thousand US$ to 1,608,400 thousand US$ by March 2026. While both metrics grew, the rate of change varied, directly impacting the asset turnover efficiency.
Phase of Efficiency Improvement (March 2022 – September 2023)
During this interval, the net fixed asset turnover ratio rose steadily from 7.18 to 8.59. This indicates that revenue growth outpaced the expansion of the fixed asset base, reflecting increased operational efficiency and a higher yield of sales per unit of net fixed investment.
Peak and Volatility (2024)
A significant peak in the turnover ratio occurred in September 2024, reaching 9.51. This spike is attributable to a temporary contraction in net property and equipment to 1,117,800 thousand US$ while revenues continued to climb to 2,771,900 thousand US$. This period represents the highest level of fixed asset utilization within the analyzed timeframe.
Capital Investment and Ratio Compression (December 2024 – March 2026)
A sustained downward trend in the turnover ratio is observed starting in late 2024, falling from 8.98 in December 2024 to 7.60 by March 2026. This decline coincides with a period of aggressive investment in property and equipment, which grew by approximately 31% between December 2024 and March 2026. The decrease in the ratio suggests that the expansion of the fixed asset base is currently outpacing revenue growth, a pattern typical of companies investing in future capacity that has not yet reached full revenue-generating potential.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
 
Property and equipment, net
Operating lease assets
Property and equipment, net (including operating lease, right-of-use asset)
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + ) ÷ =


The financial data indicates a distinct shift in the relationship between revenue generation and long-term asset investment from March 2022 through March 2026. While revenues maintained a consistent upward trajectory, a substantial expansion of the fixed asset base led to a significant decline in asset utilization efficiency during the latter half of the period.

Revenue Growth Trends
Revenues demonstrated steady growth, increasing from 2,097,500 thousand USD in March 2022 to 2,986,900 thousand USD by March 2026. This growth was characterized by a consistent quarterly rise, despite minor fluctuations, reflecting a strengthening top-line performance.
Property and Equipment Expansion
Net fixed assets, including right-of-use assets, remained relatively stagnant between March 2022 and March 2024, hovering around the 1.4 billion USD mark. A pivot occurred in June 2024, initiating a period of aggressive capital expansion. Assets rose sharply to 2,513,900 thousand USD by September 2024 and continued to climb, reaching 3,293,500 thousand USD by March 2026.
Net Fixed Asset Turnover Analysis
The net fixed asset turnover ratio exhibited two opposing phases. In the first phase, from March 2022 to March 2024, the ratio improved from 5.53 to a peak of 6.86, indicating that revenues were growing faster than the asset base. In the second phase, coinciding with the surge in property and equipment investments, the ratio declined sharply to 4.23 in September 2024 and continued a downward trend to reach 3.71 by March 2026. This contraction suggests that the rapid increase in long-term investments has not yet been matched by a proportional increase in revenue generation.

Total Asset Turnover

Vertex Pharmaceuticals Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Total asset turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of investment activity ratios reveals a consistent long-term decline in total asset turnover, despite steady growth in top-line revenues. The ratio decreased from 0.56 in March 2022 to 0.46 by March 2026, indicating a reduction in the efficiency with which the company utilizes its asset base to generate sales.

Revenue Growth Patterns
Revenues exhibited a generally positive trajectory over the analyzed period, rising from 2,097,500 thousand USD in March 2022 to a peak of 3,190,000 thousand USD in December 2025. While growth was sustained for most of the period, a slight contraction occurred in the final quarter, with revenues ending at 2,986,900 thousand USD in March 2026.
Asset Base Expansion
Total assets experienced substantial growth, increasing from 14,256,100 thousand USD in March 2022 to 26,484,400 thousand USD by March 2026. This significant expansion of the balance sheet suggests aggressive investment in infrastructure, acquisitions, or cash accumulation that outpaced the growth of quarterly revenues.
Asset Turnover Efficiency
The downward trend in the total asset turnover ratio reflects a widening gap between asset accumulation and revenue generation. From March 2022 through December 2023, the ratio fell steadily from 0.56 to 0.43. Although the ratio remained relatively stable between 0.43 and 0.49 from 2024 onwards, it failed to return to the efficiency levels observed at the start of the period.
Analysis of Ratio Variance
A notable anomaly occurred in June 2024, where the turnover ratio spiked to 0.51. This increase was not driven by a surge in revenue—which actually declined slightly from the previous quarter—but was instead the result of a sharp reduction in total assets, which dropped from 23,917,400 thousand USD in March 2024 to 20,132,100 thousand USD in June 2024. Following this event, assets resumed their upward trend, causing the turnover ratio to revert to its previous declining pattern.

In summary, the organization has scaled its asset base significantly over the four-year period. However, because the growth in total assets has consistently exceeded the growth in revenues, the overall asset utilization efficiency has diminished, resulting in a lower total asset turnover ratio.


Equity Turnover

Vertex Pharmaceuticals Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Equity turnover = (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025) ÷ Shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


A consistent upward trajectory in revenues is observed from March 31, 2022, through March 31, 2026. Revenues increased from 2,097,500 thousand US$ to a peak of 3,190,000 thousand US$ in December 2025, before settling at 2,986,900 thousand US$ by the end of the analyzed period. This growth indicates a steady expansion in the company's top-line performance over the four-year span.

Shareholders' equity exhibited a general growth trend, rising from 10,907,000 thousand US$ in March 2022 to 19,361,900 thousand US$ by March 2026. However, a significant contraction occurred between March 31, 2024, and June 30, 2024, where equity decreased from 18,546,600 thousand US$ to 14,774,700 thousand US$. Following this event, the equity base resumed its growth path.

Equity Turnover Trend Analysis
Between March 31, 2022, and March 31, 2024, the equity turnover ratio experienced a continuous decline, falling from 0.73 to 0.55. This downward trend suggests that shareholders' equity grew at a faster rate than revenues during this period, leading to a decrease in the efficiency of equity utilization for generating sales.
Impact of Equity Contraction
A sharp reversal in the turnover trend occurred on June 30, 2024, with the ratio jumping from 0.55 to 0.70. This spike was primarily driven by the substantial reduction in shareholders' equity rather than a corresponding surge in revenue, effectively resetting the ratio to levels seen in early 2022.
Period of Stabilization
From June 30, 2024, through March 31, 2026, the equity turnover ratio remained relatively stable, fluctuating within a narrow range between 0.63 and 0.70. This indicates a period of relative equilibrium where revenue growth and equity accumulation moved more closely in tandem.